Kornimate/medical-research-clean huggingface dataset:
the safe effective light dose of photodynamic therapy for chronic central serous chorioretinopathy

Conditions: Central Serous Chorioretinopathy

Summary: to find the safe effective lowest light dose for photodynamic therapy (pdt). in the treatment of central serous chorioretinopathy.


Eligibility criteria:
inclusion criteria: 1. idiopathic detachment of the neurosensory retina with a focal leak at the level of the rpe with fa 2. presence of srf and/or serous pigment epithelial detachment on optical coherence tomography (oct) 3. presence of abnormal dilated choroidal vasculature in icga 4. patients with symptomatic csc of at least 3 months duration exclusion criteria: 1. patients who received any previous treatment, including pdt or focal thermal laser photocoagulation for csc, or who had evidence of cnv, pcv, or other maculopathy on clinical examination, fa, or icga 2. patients receiving exogenous corticosteroid treatment 3. patients with systemic diseases such as cushing's disease or renal diseases 4. pregnant patients

Keywords: central serous chorioretinopathy photodynamic therapy safe and effective dose
mandala colouring on anxiety, depression, pain and quality of life

Conditions: Hemodialysis Patients

Summary: the research was conducted as an experimental research to determine the effect of mandala painting on pain, anxiety, depression and quality of life in patients undergoing hemodialysis.

the effect of mandala painting on pain, anxiety, depression and quality of life in patients undergoing hemodialysis.

Eligibility criteria:
inclusion criteria: be over 18 ability to communicate adequately absence of psychiatric problems volunteering to participate in the research receiving hemodialysis treatment for at least 3 months exclusion criteria: none

Keywords: hemodialysis anxiety depression pain quality of life mandala painting
bolus of saline in stroke

Conditions: Ischemic Stroke

Summary: this study is a non-randomized, phase 2 clinical trial designed to assess optical cerebral blood flow (cbf) response to bolus normal saline. subjects will have had an ischemic stroke within 96 hours of enrollment. the study intervention will be a one hour monitoring session. there will be a 15 minute baseline measurement period, followed by intravenous administration of 500cc of 0.9% nacl over 30 minutes, and finally 15 minutes of monitoring post-bolus. all study measurements will cease after 1 hour. subjects will be followed during their hospitalization for 7 days or until discharge, whichever is sooner, to monitor for adverse events and to collect clinical information.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * acute ischemic stroke in the territory of the anterior, middle, or posterior cerebral artery territory on either side of the brain * study intervention can be initiated within 96 hours of symptom onset * willingness and ability to sign informed consent by patient or legally acceptable surrogate decision-maker exclusion criteria: * infarct limited to the brainstem and/or cerebellum with no involvement of the cerebral hemispheres * bi-hemispheric infarction or acute infarct in the contra-lateral hemisphere within the past 30 days * symptoms of active congestive heart failure (dyspnea, orthopnea, increased oxygen requirement) * exacerbation of congestive heart failure, requiring hospitalization, within the past 30 days or severe systolic dysfunction with a known ejection fraction \<20% * end stage renal disease requiring hemodialysis or a creatinine clearance \<20 ml/min/1.73 m2 * hemicraniectomy or other skull defect that would interfere with monitoring * pregnant women are excluded. women of child-bearing age must have a negative pregnancy test prior to enrollment * participation in another clinical trial * any other illness or condition that the investigator feels would pose a hazard to the subject from participation in the study
pharmacokinetics of oral antiplatelet agents after distal gastrectomy

Conditions: Stomach Neoplasm; Cardiovascular Diseases; Cerebrovascular Disease

Summary: this study is aimed to investigate the changes in pharmacokinetics and efficacy of antiplatelet agents before and after distal gastrectomy in gastric cancer patients taking oral antiplatelet agents for primary or secondary treatment for cardiovascular disease and to evaluate its impact on the occurrence of postoperative bleeding complications and thromboembolic events.


Eligibility criteria:
inclusion criteria: * patients diagnosed with pathologically proven gastric cancer of clinical stage i according to the ajcc 8th edition. * patients who are scheduled to undergo distal gastrectomy (access: either minimally invasive surgery or open surgery) * patients taking aspirin and/or clopidogrel for primary or secondary prevention for cardiovascular disease or cerebrovascular disease before surgery. * age 18 - 90 years * a person who voluntarily agrees to participate in this study and signs the consent form. exclusion criteria: * patients with coagulation disorder or abnormal findings in coagulation test (low platelet count, prolonged pt/aptt) * patients taking other anticoagulants in combination * patients with imparied liver or renal function that may affect drug metabolism. impaired liver function: liver cirrhosis impaired renal function: ckd grade 3 or higher * patients requiring adjuvant chemotherapy after surgery that may affect postoperative bone marrow function and hematopoietic function (those with gastric cancer of clinical stage ii or more according to the ajcc 8th edition) * patients participating in other clinical trials within 6 months * vulnerable patients (pregnant women, those with cognitive impairment, etc)
assessment of novel sound changing principles in hearing instruments to determine their application - 2019_04

Conditions: Hearing Loss

Summary: participants will take part in both a passive and active emotion recognition task: (1) passively listening to semantically-neutral sentences with emotional prosody, and (2) actively listening and subsequently categorizing emotional sentences and sounds. participants are seated and instructed to stare at a fixation cross while the stimulus is played. during this study, non-invasive physiological measurements of pupil dilation will be recorded from the participants. using this paradigm we will be assessing the effect of frequency lowering on emotion recognition. the study takes the form of a partly three factorial design (passive task x frequency lowering x acclimatization). participants also perform a two factor design (active task x frequency lowering). each participant performs two passive tests (20 minutes long each) with frequency lowering on and off, and a four week acclimatization period in-between. participants perform one active listening task after the acclimatization period with frequency lowering on and off.


Eligibility criteria:
inclusion criteria: * healthy outer ear (without previous surgical procedures) * ability to fill in a questionnaire conscientiously * informed consent as documented by signature * minimum 1 year hearing aid experience * moderate-severe (n3-n5) hearing loss or normal hearing exclusion criteria: * contraindications to the md in this study, e.g. known hypersensitivity or allergy to the investigational product * limited mobility and not in the position to attend weekly appointments * inability to produce a reliable hearing test result * massively limited dexterity * known psychological problems * known central hearing disorders
clinical trial to assess the efficacy and safety of mucolase tablet(streptokinase • streptodornase)

Conditions: Acute Upper Respiratory Infection; Acute Bronchitis

Summary: a phase 4 study to evaluate efficacy and safety of mucolase tablet (streptokinase • streptodornase)

double-blind, randomized, placebo controlled, multicenter, phase 4 clinical trial to assess the efficacy and safety of mucolase tablet (streptokinase • streptodornase) in patients with acute upper respiratory infection or acute bronchitis

Eligibility criteria:
inclusion criteria: * 19≤ age * patients with acute upper respiratory infection or acute bronchitis * patients with cough and phlegm within 48 hrs as of visit 1 * patients understood the consents and purpose of this trial and signed consent form exclusion criteria: * patients with high fever (≥39℃) * patients with severe respiratory diseases (ex) bronchial asthma, pneumonia, pulmonary tuberculosis, bronchiectasis, mucus sticking, chronic obstructive pulmonary disease (copd), etc. * patients with a history of hypersensitivity to drug * patients with abnormal blood coagulation * patients with thrombocytopenia * patients with uncontrolled hypertension * patients with a severe liver disorder(ast or alt level exceeds 2 times more than normal upper range) * patients woth a clinically significant renal failure(mdrd egfp \< 60 ml/min/1.73m2)
oral enteral nutrition in delayed onset radiotherapy-related swallowing disorder in nasopharyngeal carcinoma

Conditions: Dysphagia

Summary: this is a prospective multicenter study with patients with delayed dysphagia after radiotherapy for npc. patients enrolled are randomly divided equally into the observation group and the control group. all patients receive conventional care, and the observation group received ioe while the control group received ngt for enteral nutrition support. baseline information (demographics, medical history, etc.), nutritional status at admission and after treatment, depression, dysphagia, and quality of life (qol) after treatment as well as adverse events are compared.

palliation to delayed dysphagia after radiotherapy for nasopharyngeal carcinoma (npc) continues to be a challenge. although nasogastric tube feeding (ngt) has been adopted widely, the weaknesses have yet to be improved by another enteral nutrition support mode. this study aims to observe the clinical efficacy of intermittent oro-esophageal tube feeding (ioe) in the treatment of delayed dysphagia after radiotherapy for (npc). this is a prospective multicenter study with patients with delayed dysphagia after radiotherapy for npc. patients enrolled are randomly divided equally into the observation group and the control group. all patients receive conventional care, and the observation group received ioe while the control group received ngt for enteral nutrition support. baseline information (demographics, medical history, etc.), nutritional status at admission and after treatment, depression, dysphagia, and quality of life (qol) after treatment as well as adverse events are compared.

Eligibility criteria:
inclusion criteria: * age between 18 and 65 years. * with the history of nasopharyngeal carcinoma and radiation therapy. * with dysphagia occurred at least three years after radiotherapy (confirmed by videofluoroscopic swallowing study), in need of and feasible for enteral nutrition support. * conscious and with stable vital signs; * willing to participate and sign the written informed consent form either personally or by a family member. exclusion criteria: * presence of other diseases that might cause dysphagia. * with distant metastasis of tumors, or complicated with severe systemic disorders or malignancies. * concurrent participation in other treatments that could interfere with the trial. * inability to cooperate with treatment due to aphasia, mental health issues, etc. * received tube feeding for enteral nutrition support within the past three years.
a multi-center, randomized, open-label study to assess the immunogenicity and safety of denosumab in pre-filled syringe compared to vial in subjects with low bone mineral density

Conditions: Low Bone Mineral Density; Osteopenia; Osteoporosis

Summary: the purpose of this study is to compare the immunogenicity profiles of denosumab pre-filled syringe (pfs) and vial at 6 months in postmenopausal women with low bone mineral density (bmd).


Eligibility criteria:
inclusion criteria: * patients who have successfully completed the 20050141 study (nct00330460): * must have received all sc investigational product administrations in 20050141 * must not have taken any proscribed therapies in 20050141 * subjects who were in the alendronate or denosumab treatment group are allowed * provide signed informed consent before any study-specific procedures are conducted exclusion criteria: * any disorder that, in the opinion of the investigator, may compromise the ability of the patient to give written informed consent and/or comply with study procedures including: * any physical or psychiatric disorder * or evidence of alcohol or substance abuse in the last 12 months * any clinical evidence, in the medical judgement of the investigator, of the following medical conditions: * impaired thyroid function (subsequent to treatment) * impaired hepatic function * impaired renal function * rheumatoid arthritis, paget's disease, cushing's disease, hyperprolactinemia, or cirrhosis of the liver * known to have tested positive for human immunodeficiency virus, hepatitis c virus, or hepatitis b surface antigen * any metabolic bone disease, eg, osteomalacia or osteogenesis imperfecta, which may interfere with the interpretation of the findings

Keywords: osteopenia osteoporosis amg 162 postmenopausal pre-filled syringe
comparison of lifestyle markers between women with and without polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome; Dietary Habits; Physical Activity

Summary: the purpose of the study is to identify lifestyle factors associated with pcos and understand how diet and activity levels impact features of pcos. the secondary aim is to examine psychosocial factors (e.g., health beliefs) of women with pcos.

polycystic ovary syndrome (pcos) is an endocrine disorder that affects 6-12% of reproductive-aged women within the general population. currently, there is limited knowledge on the current lifestyles of women with pcos and the psychosocial factors associated with pcos. the researchers plan to examine potential lifestyle differences and psychosocial factors between pcos and healthy women. the research team is also interested in the relationships between biological markers and lifestyle endpoints in women with and without pcos. previous literature has shown there are biological marker differences between those with and without pcos. by examining these relationships, researchers may further understand whether pcos status is associated with lifestyle parameters. to accomplish these objectives, 360 women (120 women with pcos, 120 women without pcos and with normal menstrual cycles, and 120 women without pcos and with irregular menstrual cycles) will be included in this study. an equal number of lean and overweight/obese women will be recruited within each group based on body mass index (bmi; lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2). women will be included in the pcos group if they have a confirmed pcos diagnosis from their primary care provider. participants will complete a food frequency questionnaire, a sleep questionnaire, and a physical activity questionnaire. a researcher may also provide participants with a waist-worn accelerometer to monitor physical activity and a wrist-worn accelerometer to monitor sleep for a week. ultrasound scans of the ovaries will be assessed and the following metabolic parameters will be assessed: (1) 75-gram oral glucose tolerance test; (2) dual x-ray absorptiometry (dxa) scan; (3) vitals and anthropometry assessment to measure waist and hip circumference, height, weight, blood pressure, and heart rate; (4) fasting blood tests to detect androgens (i.e., total testosterone, androstenedione, free androgen index); and (5) an (optional) subcutaneous fat biopsy. women with and without pcos will also be asked to complete a questionnaire that will assess the psychosocial factors (e.g., health beliefs). this can be conducted online, in person, or through phone.

Eligibility criteria:
inclusion criteria: * between 18 and 48 years * bmi ≥ 18 kg/m2 * if ≥ 21 years old, must have completed a pelvic exam in the past 2 years * in pcos if: confirmed pcos diagnosis from their primary care provider exclusion criteria: * use of oral contraceptives, fertility medications, or any drugs known to influence reproductive function * pregnant or breastfeeding

Keywords: polycystic ovary syndrome (pcos) diet exercise questionnaires health beliefs
post-radiotherapy rhinosinusitis in children

Conditions: Pediatric Cancer; Chronic Sinusitis

Summary: chronic rhinosinusitis (crs) is a frequent complication of facial cancer treatment, mainly related to radiotherapy. however, while radiological involvement is frequent, clinical expression seems less important. few studies have investigated the incidence of this condition in the pediatric population while its evolution seems to be very chronic even if a partial improvement may occur with time. our objective is therefore to study the impact of csr in children treated for cancer of the cervicofacial region, to evaluate its incidence and medium-term evolution in order to determine whether it is necessary to set up a specific follow-up in these patients. the clinical impact of csr is assessed by a specific snot 22 questionnaire in children treated for a head-neck mesenchymal malignancy in comparison with a control population consisting of children treated for a mesenchymal malignancy of non-head-neck location.


Eligibility criteria:
inclusion criteria: * study population: all patients under 18 years of age managed for a head neck mesenchymal cancer between january 1, 2018 and december 31, 2024 * control population: all patient under 1 years of age managed for non -head neck mesenchymal cancer between january 1, 2018 and december 31, 2024 exclusion criteria: * patients with hematological tumors; * patients with mucociliary pathologies or proven allergic rhinitis before the diagnosis of cancer * patients who have required surgical treatment that has removed more than half of the sinus cavities * tumor recurrence at the time of inclusion * sinus surgery between the last radiological check-up and inclusion * administrative reasons: inability to receive informed information.

Keywords: post-treatment chronic sinusitis pediatric cancer sinusitis quality of life
the ultrasonographic changes of intercostal muscles and diaphragm in mechanically ventilated preterm neonates

Conditions: Mechanical Ventilation Complication

Summary: invasive mechanical ventilation induces ventilator induced diaphragmatic dysfunction particularly when used for long time and intercostal muscles as well contribute to the important work of respiratory movement by expanding the thorax , and determining the thickness of them would be a useful parameter in evaluating respiratory muscle activity. this study will add the impact of mechanical ventilation on the diaphragm and intercostal muscles in preterm infants using ultrasound.


Eligibility criteria:
inclusion criteria: 1. preterm infants from 28-36 weeks gestation 2. in need for invasive mechanical ventilation according to work of breathing, oxygen saturation and blood gases . exclusion criteria: * 1) significant congenital anomalies including cardiac, abdominal or respiratory. 2) congenital anomalies involving the diaphragm. 3) phrenic nerve paralysis. 4) congenital muscular dystrophies. 5) major upper or lower airway anomalies. 6) storage diseases.
neurological effects of goal-directed fluid therapy in beach chair position shoulder surgery

Conditions: Postoperative Cognitive Dysfunction; Anesthesia

Summary: patients receiving beach chair position shoulder surgery are vulnerable to perioperative cerebral desaturation, which is reported to be a risk factor for postoperative cognitive dysfunction. investigators design this study to test the efficacy of perioperative goal-directed therapy in preventing cerebral desaturation and postoperative cognitive dysfunction in patients receiving beach chair position shoulder surgery.


Eligibility criteria:
inclusion criteria: * patients receiving scheduled beach chair position shoulder surgery exclusion criteria: * pregnant women * patients in intensive care units * patients with respiratory failure \[forced expiratory volume at one second (fev1)/ forced vital capacity (fvc) \< 70 % and fev1 \< 50%\] * patients with heart failure(nyha score =iii、iv) * patients with chronic kidney disease (egfr\< 60 ml.min-1.1.73m-2) * patients with liver failure * patients with ongoing infection * patients allergic to voluven
impact of the probefix on the workflow of pharmacological stress echocardiography examinations

Conditions: Coronary Artery Disease

Summary: pharmacological stress-echocardiography examinations are routinely performed in daily clinical practice. usually, the echo probe is manually placed on the patient's thorax by the physician. the probefix is a novel device, enabling the fixation of the ultrasound probe on the patient's thorax. therefore, there is no need to manually hold the probe. this may improve the standardization of the examination and my reduce its duration. the present trial will investigate, whether the utilization of the probefix reduces the duration of stress-echocardiography examinations and improves standardization of image acquisition.


Eligibility criteria:
inclusion criteria: * patients undergoing clinically indicated pharmacological stress-echocardiography * willingness to participate exclusion criteria: * pharmacological stress echocardiography indication other than evaluation of stress induced ischemia (e.g. low-flow-low-gradient aortic valve stenoseis) * poor image quality * early termination of the stress-echocardiography examination for clinical reasons